Suttorp, Meinolf, Schulze, Philipp, Glauche, Ingmar, Goehring, Gudrun, von Neuhoff, Nils, Metzler, Markus, Sedlacek, Petr, de Bont, Eveline S. J. M., Balduzzi, Adriana, Lausen, Birgitte, Aleinikova, Olga, Sufliarska, Sabina, Henze, Guenter, Strauss, Gabriele, Eggert, Angelika, Kremens, Bernhard, Groll, Andreas H., Berthold, Frank, Klein, Christoph, Gross-Wieltsch, Ute, Sykora, Karl Walter, Borkhardt, Arndt, Kulozik, Andreas E., Schrappe, Martin, Nowasz, Christina, Krumbholz, Manuela, Tauer, Josephine T. ORCID: 0000-0002-6079-4653, Claviez, Alexander, Harbott, Jochen, Kreipe, Hans H., Schlegelberger, Brigitte and Thiede, Christian (2018). Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 32 (7). S. 1657 - 1670. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib upfront (300, 400, 500 mg/m(2), respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Suttorp, MeinolfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schulze, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glauche, IngmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goehring, GudrunUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Neuhoff, NilsUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzler, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sedlacek, PetrUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Bont, Eveline S. J. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balduzzi, AdrianaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lausen, BirgitteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aleinikova, OlgaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sufliarska, SabinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Henze, GuenterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Strauss, GabrieleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eggert, AngelikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kremens, BernhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Groll, Andreas H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berthold, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klein, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gross-Wieltsch, UteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sykora, Karl WalterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borkhardt, ArndtUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kulozik, Andreas E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schrappe, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nowasz, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krumbholz, ManuelaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tauer, Josephine T.UNSPECIFIEDorcid.org/0000-0002-6079-4653UNSPECIFIED
Claviez, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbott, JochenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kreipe, Hans H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlegelberger, BrigitteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thiede, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-181699
DOI: 10.1038/s41375-018-0179-9
Journal or Publication Title: Leukemia
Volume: 32
Number: 7
Page Range: S. 1657 - 1670
Date: 2018
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC MYELOGENOUS LEUKEMIA; COMPLETE MOLECULAR REMISSION; TYROSINE KINASE INHIBITORS; STEM-CELL TRANSPLANTATION; LONG-TERM SURVIVAL; MANAGING CHILDREN; DOSE IMATINIB; RECEIVING IMATINIB; RANDOMIZED CML; ADVERSE EVENTSMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/18169

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item